NasdaqGM - Nasdaq Real Time Price ? USD Merus N.V. (MRUS) Follow Compare 51.60 -1.09 (-2.07%) At close: October 21 at 4:00 PM EDT 51.60 0.00 (0.00%) After hours: October 21 at 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose... Simply Wall St. ? 4 days ago MRUS -2.07% MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains? MeiraGTx (MGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. Zacks ? 5 days ago MGTX MRUS -2.07% Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics? and Triclonics?), today announced that the first patient has been dosed in the Company’s phase 3 trial evaluating the efficacy and safety of petosemtamab, a Biclonics? targeting EGFR and LGR5, in combination with pembrolizumab, compared to pembrolizuma GlobeNewswire ? 21 days ago MRUS -2.07% TimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS) TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter the fund returned -1.59% (gross) and -1.83% (net), compared to a -2.92% return for the Russell 2000 Growth Index. The equity markets performed well in […] Insider Monkey ? last month MRUS -2.07% Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024 Petosemtamab in 2L+ HNSCC interim clinical data selected for rapid oral presentationUTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics? and Triclonics?), today announced the acceptance of an abstract on petosemtamab, a Biclonics? targeting EGFR and LGR5, in previously treated (2L+) patients with recurre GlobeNewswire ? last month MRUS -2.07% Merus NV (MRUS): Short Seller Sentiment is Bearish on This Cancer Stock We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are going to take a look at where Merus NV (NASDAQ:MRUS) stands against the other cancer stocks. Cancer is the second leading cause of death globally, just behind cardiovascular disease, making oncology one of […] Insider Monkey ? last month MRUS -2.07% Merus NV (MRUS): Top ADR Stock According to Hedge Funds We recently compiled a list of the Top 10 ADR Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Merus NV (NASDAQ:MRUS) stands against the other ADR stocks. Diversifying an investment portfolio is one of the best ways of spreading risk and minimizing the impact of […] Insider Monkey ? last month MRUS -2.07% We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... Simply Wall St. ? 2 months ago MRUS -2.07% Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics? and Triclonics?), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at Canaccord Genuity’s 44th Annual Growth Conference on Tuesday, August 13, 2024 from 9:00-9:25 a.m. ET. The webcast of the presentation will be contemporaneously avail GlobeNewswire ? 2 months ago MRUS -2.07% Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates Merus (MRUS) delivered earnings and revenue surprises of -6.58% and 23.94%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 2 months ago MRUS -2.07% Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update – Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO? demonstrated robust 67% response rate among 24 evaluable patients – First patients dosed in phase 3 trial evaluating petosemtamab monotherapy in 2/3L HNSCC, phase 2 trial evaluating petosemtamab in combination with standard chemotherapy in 2L mCRC, and phase 2 trial evaluating MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC – Based on the Company’s current operating plan, existing cash, cash equiva GlobeNewswire ? 2 months ago MRUS -2.07% Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Agenus (AGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Zacks ? 2 months ago AGEN MRUS -2.07% Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Merus (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Zacks ? 2 months ago MRUS -2.07% PRTA Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedbackUTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics? and Triclonics?), today announced that the first patient has been dosed in the Company’s phase 3 trial evaluating the GlobeNewswire ? 2 months ago MRUS -2.07% Institutional investors control 69% of Merus N.V. (NASDAQ:MRUS) and were rewarded last week after stock increased 5.5% Key Insights Significantly high institutional ownership implies Merus' stock price is sensitive to their trading... Simply Wall St. ? 3 months ago MRUS -2.07% Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics? and Triclonics?), today announced that the first patient has been dosed in the Company’s phase 2 trial evaluating petosemtamab in combination with standard chemotherapy in second line (2L) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics GlobeNewswire ? 3 months ago MRUS -2.07% Sector Update: Health Care Stocks Retreat Late Afternoon Sector Update: Health Care Stocks Retreat Late Afternoon PREMIUM MT Newswires ? 3 months ago WBA MRUS -2.07% Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics? and Triclonics?), today announced the appointment of Fabian Zohren M.D., PhD as Chief Medical Officer (CMO) effective July 1, 2024. Andrew Joe, M.D. will step down from the CMO role and continue to serve as a Consultant for the next three months. In add GlobeNewswire ? 3 months ago MRUS -2.07% Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO? Annual Meeting UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics? and Triclonics?), today announced the publication of a poster regarding MCLA-129 presented at the 2024 American Society of Clinical Oncology? (ASCO?) Annual Meeting taking place in Chicago May 31-June 4, 2024. “These data continue to support our view th GlobeNewswire ? 4 months ago MRUS -2.07% Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO? Annual Meeting UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics? and Triclonics?), today announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology? (ASCO?) Annual Meeting taking place in Chicago May 31-June 4, GlobeNewswire ? 4 months ago MRUS -2.07% Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return MRUS S&P 500 YTD +87.64% +22.73% 1-Year +154.19% +38.58% 3-Year +81.24% +29.05%
